Evrofarma Past Earnings Performance
Past criteria checks 1/6
Evrofarma has been growing earnings at an average annual rate of 36.3%, while the Food industry saw earnings growing at 10.2% annually. Revenues have been growing at an average rate of 9.7% per year. Evrofarma's return on equity is 12.4%, and it has net margins of 4.7%.
Key information
36.3%
Earnings growth rate
36.3%
EPS growth rate
| Food Industry Growth | 7.7% |
| Revenue growth rate | 9.7% |
| Return on equity | 12.4% |
| Net Margin | 4.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
A Piece Of The Puzzle Missing From Evrofarma SA's (ATH:EVROF) Share Price
Dec 19
Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders
Oct 02Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%
Feb 29Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company
Jan 06Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled
Jan 05Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet
Dec 01Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital
Sep 15Is Evrofarma (ATH:EVROF) Using Too Much Debt?
May 27We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings
Oct 04Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture
May 19Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?
Feb 22Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital
Dec 29
Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?
Nov 22Revenue & Expenses Breakdown
How Evrofarma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 47 | 2 | 5 | 0 |
| 31 Mar 24 | 48 | 2 | 5 | 0 |
| 31 Dec 23 | 49 | 2 | 5 | 0 |
| 30 Sep 23 | 49 | 3 | 5 | 0 |
| 30 Jun 23 | 49 | 3 | 5 | 0 |
| 31 Mar 23 | 47 | 2 | 5 | 0 |
| 31 Dec 22 | 45 | 1 | 5 | 0 |
| 30 Sep 22 | 42 | 0 | 5 | 0 |
| 30 Jun 22 | 39 | -1 | 5 | 0 |
| 31 Mar 22 | 38 | -1 | 5 | 0 |
| 31 Dec 21 | 37 | 0 | 5 | 0 |
| 30 Sep 21 | 36 | 1 | 5 | 0 |
| 30 Jun 21 | 36 | 1 | 5 | 0 |
| 31 Mar 21 | 35 | 1 | 5 | 0 |
| 31 Dec 20 | 34 | 1 | 5 | 0 |
| 30 Sep 20 | 33 | 1 | 5 | 0 |
| 30 Jun 20 | 32 | 0 | 5 | 0 |
| 31 Mar 20 | 33 | 0 | 5 | 0 |
| 31 Dec 19 | 33 | 0 | 5 | 0 |
| 30 Sep 19 | 34 | 0 | 5 | 0 |
| 30 Jun 19 | 35 | 1 | 5 | 0 |
| 31 Mar 19 | 34 | 1 | 5 | 0 |
| 31 Dec 18 | 33 | 1 | 4 | 0 |
| 30 Sep 18 | 32 | 1 | 4 | 0 |
| 30 Jun 18 | 31 | 1 | 4 | 0 |
| 31 Mar 18 | 31 | 1 | 4 | 0 |
| 31 Dec 17 | 31 | 1 | 4 | 0 |
| 30 Sep 17 | 31 | 0 | 4 | 0 |
| 30 Jun 17 | 30 | 0 | 4 | 0 |
| 31 Mar 17 | 30 | 0 | 4 | 0 |
| 31 Dec 16 | 29 | 0 | 4 | 0 |
| 30 Sep 16 | 28 | 0 | 4 | 0 |
| 30 Jun 16 | 28 | 0 | 4 | 0 |
| 31 Mar 16 | 30 | 0 | 4 | 0 |
| 31 Dec 15 | 30 | 1 | 4 | 0 |
| 30 Sep 15 | 29 | 0 | 4 | 0 |
| 30 Jun 15 | 28 | 0 | 5 | 0 |
| 31 Mar 15 | 26 | 0 | 5 | 0 |
| 31 Dec 14 | 25 | 0 | 5 | 0 |
| 30 Sep 14 | 25 | 0 | 5 | 0 |
| 30 Jun 14 | 25 | 0 | 5 | 0 |
| 31 Mar 14 | 24 | 0 | 4 | 0 |
Quality Earnings: EVROF has a large one-off gain of €686.0K impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: EVROF's current net profit margins (4.7%) are lower than last year (5.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EVROF's earnings have grown significantly by 36.3% per year over the past 5 years.
Accelerating Growth: EVROF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: EVROF had negative earnings growth (-23.5%) over the past year, making it difficult to compare to the Food industry average (18.2%).
Return on Equity
High ROE: EVROF's Return on Equity (12.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 13:14 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evrofarma SA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|